Earlens closes $118m in mixed debt and equity round

05 June 2017

Earlens said today it closed a total of $118 million in funding, with $73 million coming from an offering of Series C preferred stock and $45 from a structured debt facility with CRG LP. The Earlens device, which won 510(k) clearance from the FDA in October 2015, uses a laser diode attached to a behind-the-ear […]

Continue Reading

Bicycle Therapeutics Closes £40 Million ($52 Million) In Series B Financing To Advance Clinical Pipeline

01 June 2017

Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) product platform, today announced the successful completion of a £40 million Series B financing round. Proceeds will be used to further the development of multiple drug candidates, including Bicycle’s lead molecule, BT1718, a first-in-class drug for cancers […]

Continue Reading